Irritable Bowel Syndrome With Constipation (IBS-C)
Gastroenterology
2
Pipeline Programs
2
Companies
2
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
1100%
On Market (1)
Approved therapies currently available
U
LINACLOTIDEApproved
linaclotide
Unknown Companyoral2023
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Astellaslinaclotide
Astellaslinaclotide
Clinical Trials (2)
Total enrollment: 2,975 patients across 2 trials
Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
Start: Oct 2014Est. completion: Mar 2016500 patients
Phase 3Completed
Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
Start: Oct 2017Est. completion: Dec 20212,475 patients
N/ACompleted
Related Jobs in Gastroenterology
Specialty Representative, Gastroenterology – Minneapolis, Minnesota
AbbVie
Remote
11h ago
Head of Drug Product Development
Ironwood Pharmaceuticals
Boston, Massachusetts, United States
12h ago
$246K - $287K/yr
Regulatory Affairs Associate
Ferring Pharmaceuticals
Istanbul, Turkey
Yesterday
Key Account Director, Diagnostics and Research
Tempus
Remote
Yesterday
$150K - $200K/yr
QA Operation Platform Lead
Johnson & Johnson
Yokneam, Haifa District, Israel
Yesterday
Value Architecture & Engineering Lead
Johnson & Johnson
Titusville, New Jersey, United States of America
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space